April 09, 2026

Dannah Raz, MD, MPH, Named to Modern Healthcare’s 40 Under 40

Phoenix Children’s, one of the top-ranked pediatric health systems in the West, announced that Dannah Raz, MD, MPH, division chief of developmental and behavioral pediatrics, has been named to Modern Healthcare’s 40 Under 40 for 2026

Phoenix Children's Medical Connection

April 09, 2026

Medical Oddities: Tattoos and Teeth Share Work Struggles

From unexpected workplace parallels to kitchen-counter experiments and a few clinical twists, this set of stories covered more ground than your average shift.

Conexiant

April 07, 2026

Maternal Diabetes and the Hidden Risk of ROP

Retrospective cohort study links maternal diabetes to increased ROP risk in premature infants

The Ophthalmologist

April 06, 2026

Phoenix Children’s Designated a GLUT1 Deficiency Collaborative Care Network Site

Phoenix Children’s is officially a GLUT1 Deficiency Collaborative Care Network site, highlighting their expertise in rare neurological care and ketogenic diet therapy i

Phoenix Children's Medical Connection

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 06, 2026

Can Insoles Detect Disease Early?

AI-powered wearable identifies gait changes linked to neurological and musculoskeletal conditions

The Pathologist

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 26, 2026

Turning Baby Teeth Into Cell Therapy

SHED cells show early promise as a potential regenerative therapy in cerebral palsy research

The Medicine Maker

March 20, 2026

FDA Clears Setmelanotide for Hypothalamic Obesity

First and only FDA-approved therapy showed an 18.4% placebo-adjusted BMI reduction at 52 weeks

Conexiant